A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Last updated: February 17, 2025
Sponsor: Eisai Co., Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Alzheimer's Disease

Memory Loss

Dementia

Treatment

No Intervention

Clinical Study ID

NCT06322667
BAN2401-J081-401
  • Ages > 18
  • All Genders

Study Summary

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All participants who are treated with lecanemab in routine clinical practice

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 5000
Treatment Group(s): 1
Primary Treatment: No Intervention
Phase:
Study Start date:
February 14, 2024
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • Eisai trial site 2

    Hiroshima,
    Japan

    Active - Recruiting

  • Eisai trial site 3

    Kyoto,
    Japan

    Active - Recruiting

  • Eisai trial site 1

    Tokyo,
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.